𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Economic analyses: New endpoints for clinical trials

✍ Scribed by Andre Konski; Perry Grigsby

Book ID
103727168
Publisher
Elsevier Science
Year
1996
Tongue
English
Weight
210 KB
Volume
35
Category
Article
ISSN
0360-3016

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Endpoints and clinical trial design for
Endpoints and clinical trial design for nonalcoholic steatohepatitis
✍ Arun J. Sanyal; Elizabeth M. Brunt; David E. Kleiner; Kris V. Kowdley; Naga Chal πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 155 KB πŸ‘ 1 views

Nonalcoholic fatty liver disease is a common cause of chronic liver disease in the general population. Nonalcoholic steatohepatitis (NASH), the aggressive form of nonalcoholic fatty liver disease, is associated with an increased risk of liver-related mortality and cardiovascular disease. At present,

Grasping premanifest Huntington's diseas
Grasping premanifest Huntington's disease – shaping new endpoints for new trials
✍ Ralf Reilmann; Stefan Bohlen; Thomas Klopstock; Andreas Bender; Adolf Weindl; Ph πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 958 KB

## Abstract Future clinical trials in subjects with premanifest Huntington's disease (preHD) may depend on the availability of biomarkers. It was previously shown in symptomatic HD that, the grip force variability coefficient‐of‐variation (GFV‐C) in a grasping paradigm was correlated to the Unified